<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03371836</url>
  </required_header>
  <id_info>
    <org_study_id>onfi90037</org_study_id>
    <nct_id>NCT03371836</nct_id>
  </id_info>
  <brief_title>Use of Clobazam for Epilepsy and Anxiety</brief_title>
  <official_title>Use of Clobazam in Treating Anxiety Comorbid With Pediatric Epilepsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hugo W. Moser Research Institute at Kennedy Krieger, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hugo W. Moser Research Institute at Kennedy Krieger, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is an open label, adjunctive, proof of concept, pilot clinical trial. Pediatric&#xD;
      patients with epilepsy and clinically significant anxiety will be recruited and if enrolled&#xD;
      will receive active treatment, involving flexible dose titration of clobazam and will be&#xD;
      monitored for a period of four months. The study will be monitored and overseen by the Johns&#xD;
      Hopkins Hospital Institutional Review Board.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2017</start_date>
  <completion_date type="Actual">December 31, 2019</completion_date>
  <primary_completion_date type="Actual">December 31, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>All participants receive treatment and outcome is assessed; there is no control group.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CGI-I</measure>
    <time_frame>14-18 weeks</time_frame>
    <description>Mean of Clinical Global Impression-Improvement from baseline. (1-7 point scale; lower score equals a better outcome; 1 is the maximum improvement, 7 is the minimum improvement)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Epilepsy</condition>
  <condition>Anxiety</condition>
  <arm_group>
    <arm_group_label>Clobazam</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>open label (single treatment arm)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clobazam</intervention_name>
    <description>Clobazam is used as an adjunct medicine for all participants.</description>
    <arm_group_label>Clobazam</arm_group_label>
    <other_name>Onfi</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Established diagnosis of epilepsy, characterized by focal seizures with suspected or&#xD;
             documented localization in the temporal lobe. All participants will have active&#xD;
             epilepsy that requires treatment with anticonvulsant medication.&#xD;
&#xD;
               -  Although it is not necessary to be seizure free, a seizure baseline period will&#xD;
                  be established in the 60 days prior to enrollment into the study.&#xD;
&#xD;
               -  Current regimen of anticonvulsant drugs must have been stable for 30 days prior&#xD;
                  to entry into the study.&#xD;
&#xD;
          -  No episodes of seizure clusters of status epilepticus within 30 days prior to entry&#xD;
             into the study.&#xD;
&#xD;
          -  Established symptoms of anxiety with functional impairment.&#xD;
&#xD;
          -  A diagnosis of an anxiety disorder based on the administration of the K-SADS Male or&#xD;
             female participants equal to or above age 6 and below age 18 at the start of the&#xD;
             study. No exclusion will be made on the basis of gender or minority status.&#xD;
&#xD;
          -  Male or female participants equal to or above age 6 and below age 18 at the start of&#xD;
             the study. No exclusion will be made on the basis of gender or minority status.&#xD;
&#xD;
          -  Good general health as determined by medical history and physical examination.&#xD;
&#xD;
          -  Ability to swallow pills (participant will receive pill swallowing instruction if&#xD;
             necessary). The medicine may be cut into pieces and/or mixed with applesauce.&#xD;
&#xD;
          -  If female of childbearing age, a negative urine or serum pregnancy test must be&#xD;
             established or assured at baseline. Additionally, the participant must agree to use&#xD;
             abstinence or appropriate contraception methods or be otherwise incapable of pregnancy&#xD;
             for the duration of the study. Pregnancy test results will be shared with parent or&#xD;
             guardian. Pregnancy status (or prevention) and abstinence or contraception methods&#xD;
             will be addressed throughout the study for females of childbearing age as well as for&#xD;
             post-pubertal males.&#xD;
&#xD;
          -  Previous subjects who failed at any point to meet continuation criteria and withdrew&#xD;
             early may be considered for re-enrollment by the PI on a case-by-case basis.&#xD;
&#xD;
          -  Participant or legal caregiver capable of providing informed consent and fully capable&#xD;
             of monitoring the subject's disease process and compliance with treatment.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Previous allergic or hypersensitivity reactions to OnfiÂ® or benzodiazepines&#xD;
&#xD;
          -  Active substance abuse or dependence within 30 days of enrollment&#xD;
&#xD;
          -  DSM-V diagnosis of psychotic illness or imminent risk of harm to self or others.&#xD;
&#xD;
          -  Current standing use of benzodiazepines (except as &quot;rescue&quot; medicine)&#xD;
&#xD;
          -  Serious or unstable medical or neurologic conditions such as HIV, liver or kidney&#xD;
             disease, cancer or diabetes.&#xD;
&#xD;
          -  Participation in a previous experimental drug study within 30 days of baseline visit.&#xD;
&#xD;
          -  Estimated IQ&lt;70 as indicated by initial clinical assessment (rendering rating scales&#xD;
             invalid)&#xD;
&#xD;
          -  Insufficient capacity of caregiver or legal guardian to understand and appropriately&#xD;
             consent for study procedures&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jay Salpekar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>KKI/JH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kennedy Krieger Institute</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>November 21, 2017</study_first_submitted>
  <study_first_submitted_qc>December 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 13, 2017</study_first_posted>
  <results_first_submitted>December 28, 2020</results_first_submitted>
  <results_first_submitted_qc>February 13, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">March 4, 2021</results_first_posted>
  <last_update_submitted>February 13, 2021</last_update_submitted>
  <last_update_submitted_qc>February 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hugo W. Moser Research Institute at Kennedy Krieger, Inc.</investigator_affiliation>
    <investigator_full_name>Jay Salpekar, M.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>pediatrics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
    <mesh_term>Anxiety Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clobazam</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 12, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/36/NCT03371836/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Clobazam</title>
          <description>open label single treatment arm&#xD;
Clobazam is used as an adjunct medicine for all participants.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Open Label Single Treatment Arm</title>
          <description>open label&#xD;
Clobazam: Clobazam is used as an adjunct medicine for all participants.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13.8" lower_limit="6" upper_limit="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>CGI-I</title>
        <description>Mean of Clinical Global Impression-Improvement from baseline. (1-7 point scale; lower score equals a better outcome; 1 is the maximum improvement, 7 is the minimum improvement)</description>
        <time_frame>14-18 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clobazam</title>
            <description>open label single treatment arm&#xD;
Clobazam is used as an adjunct medicine for all participants.</description>
          </group>
        </group_list>
        <measure>
          <title>CGI-I</title>
          <description>Mean of Clinical Global Impression-Improvement from baseline. (1-7 point scale; lower score equals a better outcome; 1 is the maximum improvement, 7 is the minimum improvement)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="1" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>up to 18 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Open Label Single Treatment Arm</title>
          <description>open label&#xD;
Clobazam: Clobazam is used as an adjunct medicine for all participants.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Project Director</name_or_title>
      <organization>KennedyKrieger</organization>
      <phone>443-923-7600</phone>
      <email>Salpekar@kennedykrieger.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

